Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 4, July-August, p. 595–598

Publication type: original article

Language: English

Lack of Association Between CD28 Gene Polymorphism and Cervical Cancer in Lower Silesian Population

Brak zależności między polimorfizmem genu CD28 a występowaniem raka szyjki macicy w populacji Dolnego Śląska

Iwona Włodarska−Polińska1,, Edyta Pawlak2,, Katarzyna Suwalska2,, Tadeusz Dobosz3,, Stanisław Potoczek4,, Jan Kornafel1,, Irena Frydecka2,4,

1 Department of Oncology and Gynecological Oncology Clinic, Silesian Piasts University of Medicine in Wrocław, Poland

2 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

3 Department of Forensic Medicine, Silesian Piasts University of Medicine in Wrocław, Poland

4 Department of Hematology, Blood Neoplastic Diseases, and Bone Marrow Transplantation, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Background. The mechanisms of abnormal immune function in patients with cervical cancer are objects of several investigations. There is strong evidence that altered immunological function entails an increased risk of neoplastic disease. The CD28 gene encodes the main T−cell costimulatory molecule. Dysregulated CD28 expression has been reported in several neoplastic diseases, among them cervical cancer.
Objectives. Estimation of the association between CD28 gene polymorphism and cervical cancer.
Material and Methods. Fifty patients with cervical cancer and 72 healthy subjects were examined. The T/C transition at position 17 in intron 3 was genotyped by polymerase chain reaction followed by labeling with a SNaPshot kit and detection using a capillary genetic analyzer.
Results. The genotype, allele, and phenotype frequencies did not differ significantly between cervical cancer patients and controls.
Conclusion. The present study was unable to reveal any association between CD28 gene polymorphism and cervical cancer.

Streszczenie

Wprowadzenie. Mechanizmy zaburzeń funkcji immunologicznych u chorych na raka szyjki macicy są przedmiotem wielu badań. Wiele dowodów wskazuje na istnienie zależności między ryzykiem wystąpienia choroby nowotworowej a nieprawidłowościami funkcji układu odpornościowego. Gen CD28 koduje cząsteczkę odgrywającą kluczową rolę w kostymulacji komórek T. Zaburzenie ekspresji CD28 stwierdzono w wielu chorobach nowotworowych, między innymi w raku szyjki macicy.
Cel pracy. Ocena zależności między polimorfizmem genu CD28 a występowaniem raka szyjki macicy.
Materiał i metody. Badania przeprowadzono u 50 chorych na raka szyjki macicy i 72 zdrowych osób. Wymiana T/C w pozycji 17 w intronie 3 była genotypowana z użyciem reakcji PCR. Następnie produkty PCR znakowano techniką SNaPshot i identyfikowano z użyciem sekwenatora kapilarnego.
Wyniki. Częstość poszczególnych genotypów, alleli i fenotypów nie różniła się między grupą chorych na raka szyjki macicy i grupą kontrolną.
Wnioski. Nie stwierdzono zależności między polimorfizmem genu CD28 a występowaniem raka szyjki macicy.

Key words

CD28 gene polymorphism, cervical cancer

Słowa kluczowe

polimorfizm genu CD28, rak szyjki macicy

References (20)

  1. Morrison EA, Ho GY, Vermund SH et al.: Human papillomavirus infection and other risk factors for cervical neoplasma: case control study. Int J Cancer 1991, 49, 6–13
  2. Franco EL: The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection. Epidemiology 1991, 2, 98–106.
  3. Boyle DC, Smith JR: Infection and cervical intraepithelial neoplasia. Int J Gynecol Cancer 1999, 9, 177–186.
  4. Mandelblatt J, Kanetsky P, Eggert L et al.: Is HIV infection a cofactor for cervical squamous cell neoplasma? Cancer Epidemiol Biomarkers Prev 1999, 8, 97–106.
  5. Boćko D, Kosmaczewska A, Ciszak L, Teodorowska R, Frydecka I: CD28 costimulatory molecule – expression, structure and function. Arch Immunol Ther Exp 2002, 50, 169–177.
  6. Boćko D, Kosmaczewska A, Ciszak L, Urbaniak−Kujda D, Kapelko−Słowik K, Potoczek S, Frydecka I: Alterations in CD28 costimulatory T−cell molecule expression in neoplastic and autoimmune diseases. Adv Clin Exp Med 2004, 13, 2, 309–314.
  7. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS: Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA−4 on malignant ascites CD3+ tumour−infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinoma. Clin Exp Immunol 2000, 119, 19–27.
  8. Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, Cerundolo V, MacDonald HR, Cerottini JCh, Romero P: CD28−negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 1999, 29, 1990–1999.
  9. Kim ChW, Choi SH, Chung EJ, Lee MJ, Byun EK, Ryu MH, Bang YJ: Alteration of signal−transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology 1999, 67, 123–128.
  10. Rossi E, Matutes E, Morilla R, Owusu−Ankomah K, Heffernan AM, Catovsky D: Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996, 10, 494–497.
  11. Van de Corput L, Falkenburg JHF, Kester MGD, Willemze R, Kluin−Nelemans: Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol 1999, 93, 256–62.
  12. Cosiski−Marana HR, Santana−da−Silva J, Moreira−de−Andrade J: NK cell activity in the presence of IL−12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 2000, 78, 318–23.
  13. Włodarska−Polińska I, Frydecka I, Boćko D, Kosmaczewska A, Ciszak L, Kornafel J: Alterations of the expression of signal−transducing CD3ζ and costimulatory CD28 molecule in peripheral blood T lymphocytes in patients with cervical cancer. Adv Clin Exp Med 2004, 13, 589–594.
  14. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF: CTLA−4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001, 86, 1687–1693.
  15. Ahmed S, Ihara K, Kanemitsu S, Nakashima H, Otsuka T, Tsuzaka K, Takeuchi T, Hara T: Association of CTLA−4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology 2001, 40, 662–667.
  16. Van Veen T, Crusius JBA, van Winsen L, Xia B, Barkhof F, Pena AS, Polman CH, Uitdehaag BMJ: CTLA4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. J Neuroimmunol 2003, 140, 188–193.
  17. Djilali−Saiah I, Ouellette P, Caillat−Zucman S, Debray D, Kohn JI, Alvarez F: CTLA−4/CD28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 2001, 62,1356–1362.
  18. Heinzmann A, Plesnar C, Kuehr J, Forster J, Deichmann KA: Common polymorphisms in the CTLA−4 and CD28 genes at 2q33 are not associated with asthma or atopy. Eur J Immunogen 2000, 27, 57–61.
  19. Nakao F, Ihara K, Ahmed S, Sasaki Y, Kusuhara K, Takabayashi A, Nishima S, Hara T: Lack of association between CD28/CTLA−4 gene polymorphisms and atopic asthma in the Japanese population. Exp Clin Immunogen 2000, 17, 179–184.
  20. Piras G, Monne M, Uras A, Palmas A, Murineddu M, Arru L, Bianchi A, Calvisi A, Curreli L, Gaviano E, Lai P, Murgia A, Latte GC, Noli A, Gabbas A: Genetic analysis of the 2q33 region containing CD28−CTLA4− ICOS genes: association with non−Hodgkin’s lymphoma. Br J Haematol 2005, 129, 784–790.
© Wroclaw Medical University